LL-37 vs BPC-157

Side-by-side comparison of LL-37, BPC-157 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute LL-37 LL-37 (Human Cathelicidin Antimicrobial Peptide) Recovery BPC-157 Body Protection Compound-157 Recovery
Basics
Molecular type Human CathelicidinGastric Pentadecapeptide
Amino acids 3715
Molecular weight 4,493.3 Da1,419.5 Da
Half-life Short (hours)~4 hrs (SC)
Route(s) Subcutaneous, Topical, IntranasalSubcutaneous, Intramuscular, Oral (research only)
Mechanism & Research
Primary mechanism LL-37 disrupts microbial membranes through electrostatic interaction — its cationic amphipathic helical structure inserts into negatively charged bacterial membranes, causing lethal membrane permeabilisation. This mechan… BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o…
Research status Research Compound Research Compound
Evidence summary LL-37 has been studied extensively for wound healing, respiratory infections (including COVID-19 lung immunity), and more recently for senolytic applications. Its broad antimicrobial and immunomodulatory profile makes it… The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e…
Protocol & Dosing
Typical dose 1–5 mg per injection or topical application200–500 mcg per injection
Frequency DailyOnce or twice daily
Duration 4–8 weeks4–12 weeks
Timing Any timeNear injury site when possible
Safety
Common side effects
  • Injection site pain (cytokine release)
  • Mild erythema
  • Headache (rare)
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
Contraindications
  • Autoimmune conditions (immune stimulation)
  • Active lupus (LL-37 is a lupus autoantigen in some patients)
  • Pregnancy (no data)
  • Active malignancy (theoretical growth stimulation concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
Anti-doping Not Prohibited Prohibited (WADA S0)
Deeper reading
Related peptides BPC-157, GHK-Cu, KPV TB-500, GHK-Cu, KPV, Pentadeca Arginate
Full profile Read full LL-37 profile → Read full BPC-157 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.